文献速递脑血管病

高血压对替格瑞洛-阿司匹林与氯吡格雷-阿司匹林治疗轻型卒中或短暂性脑缺血发作疗效和安全性的影响

Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack.
PubMed 文献 · Stroke · 2022-06-03

基于CHANCE-2试验6412例携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者,按高血压状态分层分析。替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低无高血压患者的新发卒中风险(HR 0.55,95%CI 0.35-0.86),新诊断高血压者呈相似趋势(HR 0.59,95%CI 0.33-1.07),既往诊断高血压者无显著差异(HR 0.93,95%CI 0.74-1.18),交互作用P=0.04;出血风险与高血压状态无关。

要点

  • 无高血压患者中替格瑞洛-阿司匹林较氯吡格雷-阿司匹林显著降低90天内新发卒中风险(HR 0.55,95%CI 0.35-0.86)。
  • 新诊断高血压患者中该获益呈相似趋势但未达统计学显著(HR 0.59,95%CI 0.33-1.07)。
  • 既往诊断高血压患者中两组无显著差异(HR 0.93,95%CI 0.74-1.18),交互作用P=0.04。

核心结论

  • 在CHANCE-2试验中,无高血压的轻型卒中或短暂性脑缺血发作患者从替格瑞洛-阿司匹林获得的获益显著大于既往诊断高血压者,新诊断高血压者呈相似获益趋势。

研究设计与样本

  • 基于CHANCE-2试验随机对照数据的分析,共纳入6412例携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者,随机分配至替格瑞洛-阿司匹林组或氯吡格雷-阿司匹林组。
  • 根据病史、血压及住院期间降压药物使用情况,将高血压状态分为无高血压、新诊断高血压和既往诊断高血压。
  • 主要疗效和安全结局为90天随访内的卒中复发和中重度出血风险。

主要发现

  • 无高血压患者中,替格瑞洛-阿司匹林组新发卒中32例(4.8%),氯吡格雷-阿司匹林组60例(7.2%),HR 0.55(95%CI 0.35-0.86)。
  • 新诊断高血压患者中,替格瑞洛-阿司匹林组新发卒中20例(5.3%),氯吡格雷-阿司匹林组36例(9.1%),HR 0.59(95%CI 0.33-1.07)。
  • 既往诊断高血压患者中,替格瑞洛-阿司匹林组新发卒中139例(7.0%),氯吡格雷-阿司匹林组147例(7.4%),HR 0.93(95%CI 0.74-1.18),交互作用P=0.04。
  • 替格瑞洛-阿司匹林的出血风险与高血压状态无关:无高血压0.1% vs 0.4%,新诊断高血压0.3% vs 0.5%,既往诊断高血压0.4% vs 0.3%,交互作用P=0.50。
  • 按入院时血压水平分层,两组间所有疗效和安全性结局均无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension is a risk factor of poor stroke outcomes and associated with antiplatelet resistance. This study aimed to explore the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in patients with different hypertension status, using randomized trial data from the CHANCE-2 trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events-II). METHODS: A total of 6412 patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles were enrolled and randomized to either ticagrelor-aspirin or clopidogrel-aspirin group. Hypertension status were classified into no, newly diagnosed, and previously diagnosed hypertension according to medical history, blood pressure, and antihypertensive medications during hospitalization. The primary efficacy and safety outcomes were stroke recurrence and moderate to severe bleeding risk within 90-day follow-up. RESULTS: Ticagrelor-aspirin was associated with reduced risk of new stroke in patients without hypertension (32 [4.8%] versus 60 [7.2%]; hazard ratio, 0.55 [95% CI, 0.35-0.86]), but not in those with a newly diagnosed hypertension (20 [5.3%] versus 36 [9.1%]; hazard ratio 0.59 [95% CI, 0.33-1.07]), or those with a previously diagnosed hypertension (139 [7.0%] versus 147 [7.4%]; hazard ratio, 0.93 [95% CI, 0.74-1.18]) compared with clopidogrel-aspirin (P=0.04 for interaction). The risk of bleeding for ticagrelor-aspirin was not associated with hypertension status (0.1% versus 0.4%; 0.3% versus 0.5%, 0.4% versus 0.3%, P=0.50 for interaction). All the efficacy and safety outcomes between treatments did not differ by blood pressure levels on admission. CONCLUSIONS: In the CHANCE-2 trial, patients without hypertension received a significantly greater benefit from ticagrelor- aspirin than those with previous hypertension after minor stroke or transient ischemic attack, and a similar benefit trend was observed in those with newly diagnosed hypertension. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04078737.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wang A, Meng X, Tian X, et al. Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. Stroke. 2022. PMID: 35656824. doi:10.1161/STROKEAHA.122.038662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。